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1. Introduction 
1.1 Renal toxicity 
Renal toxicity associated with commonly prescribed drugs lengthens hospital stay, worsens 
prognosis, and limits the potential benefits obtained from therapy (Peracella, 2011; Servais et 
al., 2008). 
Proximal tubule preservation is a clue in strategies aimed to prevent nephrotoxicity. The 
proximal tubule is a target for filtered drugs that are reabsorbed by solvent drag or 
pinocytosis, but also for drugs that are secreted into the luminal side. 
Proximal tubules recover more than 60% of total filtered load, i.e., a single molecule of toxin 
that is filtered and reabsorbed will pass through the proximal tubule cell more than 50 times 
per day. Such a high degree of exposure implies a risk of cell damage causing a variety of 
clinical syndromes, from proximal acidosis and acquired Fanconi syndrome to tubular cell 
necrosis (Oh, 2010). This spectrum of diseases is known as acute kidney injury (AKI), which 
also includes cell death by apoptosis, anoikis, necrosis, or cell dysfunction (Lorz et al., 2006). 
Nephrotoxicity can often be expected with certain drugs, such as vancomycin, gentamicin, 
foscarnet, cisplatin, cyclosporine A (CsA), and tacrolimus. Less often, the toxic effect is 
unexpected and not predictable, as is the case with iodinated contrast agents and 
paracetamol. 
1.2 Cell death mediation 
Intrinsic pathway–mediated apoptosis and extrinsic pathway–mediated apoptosis are both 
involved in toxic proximal tubule cell death (Pabla & Dong, 2008; Servais et al., 2008; Xiao et 
al., 2011). With most of toxins, cell death is followed by detachment and anoikis. 
Paracetamol is a notable exception to this behavior. Caspases activation, mitochondrial 
depolarization, release of cytochrome C from mitochondria, cell membrane modification, 
and nucleosome formation are all hallmarks of apoptosis that are regularly observed in 
toxin-damaged proximal tubules (Camano et al., 2010). Nitric oxide, soluble oxygen radicals, 
and proinflammatory cytokines are released by damaged proximal tubules, thus amplifying 
the lesion. 
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1.3 Nephrotoxicity prevention strategies 
Overhydration is the most common maneuver to prevent toxic concentrations in urine and, 
consequently, inside the cell. However, nephrotoxicity usually requires dose adjustment or 
drug withdrawal, thus limiting effectiveness.  
Other strategies aimed at inhibiting cell drug transport or interfering with mediation of 
apoptosis also tend to interfere with the therapeutic targets and, consequently, limit the 
effectiveness of therapy (Pabla & Dong, 2008; Servais et al., 2008). 
During the last 5 years, our work on nephrotoxicity has enabled us to better understand the 
role of proximal tubule behavior in the adaptation of the kidney to toxic aggressions 
(Camano et al., 2010; Camaño-Paez et al., 2008; Neria et al., 2009; Perez et al., 2004; Tejedor et 
al., 2007). 
Therefore, not surprisingly, the search for alternative protective strategies against toxic 
damage to the proximal tubule is an important area of investigation today.  
1.4 Ability of cilastatin to prevent drug toxicity targeting the proximal tubule 
Cilastatin is an inhibitor of brush border dehydropeptidase I (DHP-I), which is present in 
renal proximal tubular epithelial cells (RPTECs). It was initially designed to inhibit 
hydrolysis and uptake of the carbapenem antibiotic imipenem, thus enabling it to be more 
easily recovered from urine (Birnbaum et al., 1985; Norbby et al., 1983). However, cilastatin 
is also able to inhibit uptake of CsA and cisplatin by RPTECs by decreasing in a dose-
dependent way the toxic effect of CsA and cisplatin on RPTECs (Camano et al., 2010; Perez 
et al., 2004). Clinical studies also support this protective role of cilastatin against CsA-
induced nephrotoxicity (Carmellini et al., 1997, 1998; Gruss et al., 1996; Markewitz et al., 
1994; Mraz et al., 1987, 1992; Tejedor et al., 2007). Experimental evidence suggests that 
cilastatin binding to brush border DHP-I could interact with apical cholesterol lipid  rafts 
(Camano et al., 2010; Perez et al., 2004; Tejedor et al., 2007). 
The aim of this brief report is to determine whether cilastatin is able to interfere with the direct 
toxic effect of several known nephrotoxic drugs on cultured RPTECs. We investigated the 
effect of cilastatin on the toxicity of gentamicin, vancomycin, iodinated contrast agent, 
amphotericin B, foscarnet, cisplatin, mannitol, chloroform, paracetamol, CsA and tacrolimus. 
We describe for the first time the effects of a drug that specifically targets the renal proximal 
tubule brush border and seems to be able to reduce accumulation and toxicity of the main 
nephrotoxic drugs by inhibiting internalization of brush border–bound lipid rafts. 
2. Methods 
2.1 Drugs 
We used commercially available parenteral formulations of gentamicin (powder, Guinama, 
Alboraya, Spain), vancomycin (powder, Combino Pharm, Barcelona, Spain), iodinate 
contrast agent (iopamidol, Laboratorios Farmacéuticos Rovi, Madrid, Spain), amphotericin B 
(Bristol Myers Squibb, Madrid, Spain), foscarnet (Foscavir, AstraZeneca, Madrid, Spain), 
cisplatin (Pharmacia, Barcelona, Spain), mannitol 20%, (Osmofundin®, Braun Medical S.A., 
Barcelona, Spain), chloroform (Scharlau, Barcelona, Spain), CsA (Sandimmun Neoral®, 
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Novartis Farmaceutica S.A., Spain), tacrolimus (Prograf®, Fujisawa S.A., Spain), and 
paracetamol (Perfalgan, Bristol Myers Squibb). The concentrations used were similar to the 
pharmacologically active recommended plasma level.  
Crystalline cilastatin was provided by Merck Sharp & Dohme S.A. (Madrid, Spain). A dose 
of 200 µg/ml was chosen, because it is cytoprotective and falls within the reference range for 
clinical use (Camano et al., 2010; Perez et al., 2004). 
All drug dilutions were performed with sterile culture medium and cilastatin, and the tested 
drugs were added simultaneously. 
2.2 Primary cultures of renal proximal tubule epithelial cells 
Porcine RPTECs were obtained as previously described (Camano et al., 2010; Perez et al., 
2004). Briefly, the cortex was sliced and incubated for 30 minutes at 37°C with 0.6 mg/ml of 
collagenase A (Boehringer Mannheim, Germany) in Ham’s F-12 medium. Digested tissue was 
then filtered through a metal mesh (250 µm), washed 3 times with Ham’s F-12 medium, and 
centrifuged using an isotonic Percoll gradient (45% [v/v]) at 20,000g for 30 minutes. Proximal 
tubules were recovered from the deepest fraction, washed, and resuspended in supplemented 
DMEM/Ham’s F-12 at a 1:1 ratio (with 25 mM HEPES, 3.7 mg/ml sodium bicarbonate, 2.5 
mM glutamine, 1% non-essential amino acids, 100 U/ml penicillin, 100 mg/ml streptomycin, 5 
x 10–8 M hydrocortisone, 5 mg/ml insulin-transferrin-sodium selenite media supplement, and 
2% fetal bovine serum). Proximal tubules were seeded at a density of 0.66 mg/ml and 
incubated at 37°C in a 95% air/5% CO2 atmosphere. Culture medium was renewed every 2 
days. RPTECs were used after they had reached confluence (80%). 
2.3 Cell death studies 
2.3.1 Nuclear morphology  
Cell nuclei were visualized following DNA staining with the fluorescent dye DAPI (Sigma-
Aldrich, Missouri, USA). Briefly, cells were seeded on cover slips in a 24-well plate, fixed in 
4% formaldehyde for 10 minutes, and permeabilized with 0.5% Triton X-100. They were 
then rinsed with PBS and incubated with DAPI (12.5 µg/ml) for 15 minutes. Excess dye was 
removed. Cells imaging was performed with the 40X PL-APO 1.25 NA oil objective of a 
Leica-SP2 confocal microscope (Leica Microsystems, Heidelberg, Germany). DAPI was 
excited with a 405 nm laser-diode. Emission between 420 nm and 490 nm was collected 
following the manufacturer’s recommendations. Six fields with ~200 cells per field were 
examined in each condition to estimate the percentage of nuclei with an apoptosis-like 
appearance.  
2.3.2 Nucleosomal quantification 
To evaluate DNA fragmentation in the context of apoptosis, RPTECs were incubated for 48 
hours under specific conditions with the nephrotoxic compounds selected. At the end of this 
period RPTECs were lysed and centrifuged at 200g for 10 minutes to remove cell debris. 
DNA and histones present in the soluble fraction were quantified using an enzyme-linked 
immunosorbent assay (Cell Death Detection ELISAPLUS kit, Boehringer Mannheim, Germany), 
as previously described (Camano et al., 2010; Perez et al., 2004).   
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2.3.3 Cell viability assay 
The cell survival assay relies on the capacity of cells to reduce 3-(4, 5- dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide (MTT) (Calbiochem, California, USA) to colored 
formazan in metabolically active cells. RPTECs were seeded onto 96-well plates and 
incubated with toxins alone or in combination with cilastatin. Twenty-four hours later, 0.5 
mg/ml of MTT was added, plates were incubated for 3 hours in the dark at 37ºC, and 100 
µL of 50% dimethylformamide in 20% SDS (pH 4.7) was added. Plates were incubated at 
37ºC overnight, and absorbance was measured at 595 nm. All assays were performed in 
triplicate.  
Alternatively, MTT assays were performed in real time, following MTT reduction on single 
cells, with an Olympus IX70 inverted microscope fitted to a spectrofluorometer SLM 
AMINCO 2000. MTT was measured by reading cell absorbance at 570 nm. 
2.4 Cell viability: Quantification of colony-forming units  
RPTECs were treated for 24 hours with CsA, tacrolimus or paracetamol in the presence or 
absence of cilastatin (200 µg/ml). Adherent cells were washed in saline serum,  
harvested with trypsin-EDTA, seeded in Petri dishes (100 mm), and cultured for 7 days in 
drug-free complete medium. Surviving adherent cells were fixed for 5 minutes  
with 5% paraformaldehyde/PBS and stained with 0.5% crystal violet/20% methanol for 2 
minutes. Excess dye was rinsed with PBS. Finally, the intracellular dye was eluted  
with 50% ethanol/50% sodium citrate 0.1 M (pH 4.2) and quantified by spectrometry  
at 595 nm.  
2.5 Cellular drug transport and accumulation  
RPTECs incubated for 24 hours with increasing concentrations of CsA, tacrolimus or 
paracetamol in the presence or absence of cilastatin (200 µg/ml), were scraped and lysed in 
400 µL of lysis buffer at 70ºC (2.22% [w/v] SDS; 19.33 % [v/v] glycerol [87% v/v]; 790 mM 
Tris HCl pH 6.8 in dH2O, phenylmethylsulfonyl fluoride, and protease inhibitors). Cell 
lysates were heated at 100ºC for 5 minutes, homogenized in ice, and centrifuged at 12,000g 
for 5 minutes at 4ºC. The supernatant was analyzed for total protein content and the 
presence of nephrotoxins. The concentrations of CsA, tacrolimus and paracetamol were 
measured using fluorescence polarization immunoassay technology on a TDX Chemistry 
Analyzer (Abbot Laboratories, USA) in accordance with the instructions provided by the 
manufacturer. The calibrators and controls supplied with each kit were applied, and the 
results were expressed as ng drug/µg protein.  
2.6 Localization of lipids rafts by immunofluorescence 
To study the interaction of cilastatin with cholesterol lipid rafts, we used FITC-conjugated 
cholera toxin B (Molecular Probes, Oregon, USA), as its internalization is mediated by  
lipid rafts. 
RPTECs cultured on glass coverslips were preincubated with culture medium alone or 
cilastatin 200 µg/ml for 15 minutes. The cells were then incubated with 10 µg/ml FITC-
labelled cholera toxin B for 1 and 2.5 hours. Cells were washed with PBS and fixed in 4% 
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formaldehyde in PBS for 10 minutes before being rinsed with PBS. The nuclei were 
counterstained with DAPI. After washing, cells were mounted in fluorescent mounting 
medium (Dako North America, Inc., Carpinteria, California). Images of the distribution of 
cholera toxin immunolocalization across membranes were obtained with the 20X PL-APO 
0.7-numerical aperture objective of a Leica-SP2 confocal microscope (Leica Microsystems). 
2.7 Dehydropeptidase I and IV activity assays 
RPTECs were incubated overnight with Gly-Phe-p-nitroanilide (DHP-I substrate; Sigma- 
Aldrich) 1mM in PBS for DHP-I activity determination or with Gly-Pro-p-nitroanilide (DHP-
IV substrate; Sigma-Aldrich) 1 mM for DHP-IV activity determination. Both activities were 
measured in the presence or absence of cilastatin (200 µg/ml). P-Nitroanilide was quantified 
in aliquots from supernatants by measuring at 410 nm absorbance. 
2.8 Statistical analysis 
Quantitative variables were expressed as the mean ± standard error of the mean (SEM). 
Differences were considered statistically significant for bilateral alpha values less than 0.05. 
Factorial ANOVA was used when more than 1 factor was considered. When a single factor 
presented more than 2 levels and the model showed significant differences between factors, 
a post-hoc analysis (least significant difference) was performed. When results are shown, 
they represent a minimum of at least 3 repeats. When possible, a quantification technique 
(e.g. dye recovery) was used to illustrate reproducibility. When figures illustrated an effect, 
paracetamol was chosen as the example. 
3. Results 
3.1 Cilastatin as a broad nephroprotective drug: reduction of toxin-induced proximal 
tubular cell death 
After 48 hours of exposure to the drugs tested, apoptosis of RPTECs measured as 
nucleosomal DNA fragmentation and migration from nuclei to cytosol was quantified and 
compared with apoptosis under the same conditions, although in the presence of cilastatin 
(Fig. 1). RPTECs exposed to toxins present different increases in the number of nucleosomes 
recovered from cytosol. Cilastatin significantly partially or totally prevented these changes 
in most of the selected drugs (Fig. 1).  
When the magnitude of cilastatin protection was plotted against the magnitude of basal cell 
death under every treatment tested, a clear linear trend was observed (r=0.839, p<0.0005). 
None of the drugs tested differed significantly from this trend (Fig. 2). 
We made a detailed study of the effect of 3 of these drugs: CsA, tacrolimus and 
paracetamol. A more selective qualitative estimation of apoptotic cell death was also 
obtained in adherent cells treated with CsA, tacrolimus, and paracetamol and stained 
with DAPI (Fig. 3). Incubation with toxins led to cell shrinkage with significant nuclear 
condensation, fragmentation, and formation of apoptosis-like bodies (see arrows). 
Cilastatin was able to reduce nuclear damage in all cases. Apoptosis-like nuclei are 
quantified in Fig. 3B, C, and D. 
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Fig. 1. Effect of cilastatin on nephrotoxin-induced apoptosis. Renal proximal tubular 
epithelial cells were exposed to CsA (1 µg/ml), gentamicin (20 mg/ml), tacrolimus (50 
ng/ml), vancomycin (600 µg/ml), cisplatin (10 µM), iodinated contrast (1 mg/ml), foscarnet 
(1 mM), mannitol (100 mosm/l), amphotericin B (10 µg/ml), chloroform (100 µg/ml), and 
paracetamol (300 µg/ml) with and without cilastatin (200 µg/ml) for 48 hours. 
Oligonucleosomal DNA fragmentation was detected by ELISA. Data are represented as the 
mean ± SEM of at least 3 separate experiments. ANOVA model: p<0.0001. *p<0.05 vs. same 
data with cilastatin.  
 
 
Fig. 2. Reduction in nucleosomal enrichment induced by cilastatin over basal nucleosomal 
enrichment induced by each toxin. Individual experimental data are provided. There is a 
common trend for all the data, suggesting a common behavior, with cilastatin protection 
being proportional to basal damage. Linear regression of “cilastatin-induced reduction” vs. 
“basal nucleosomal enrichment”, slope=0.82, r=0.839, adjusted r2=0.695, p<0.0005. 
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Fig. 3. Effects of cilastatin on the nuclear morphology of renal proximal tubular epithelial 
cells (RPTECs) during treatment with toxins. RPTECs were cultured in the presence of 
paracetamol (30, 300 and 600 µg/ml), cyclosporine (CsA, 10, 100, and 1000 ng/ml) and 
tacrolimus (5, 50, and 500 ng/ml) with or without cilastatin (200 µg/ml) for 24 hours. A, 
Example of nuclear staining with DAPI to determine whether an apoptotic-like nuclear 
morphology was present. Arrows point to fragmented, apoptotic nuclei. B, C and D, 
Quantitative approach to staining for paracetamol, CsA and tacrolimus, respectively. Data 
are represented as the mean ± SEM of at least 3 separate experiments. ANOVA models 
p<0.0001. * cilastatin effect, p<0.05; dose effect,  p<0.05. 
We quantified the functional impact of CsA, tacrolimus and paracetamol treatments on cell 
survival by measuring the percentage of adherent cells still able to reduce MTT to formazan 
after exposure to increasing doses of toxins. After 24 hours of incubation with toxins, the 
amount of surviving cells able to reduce MTT decreases progressively as the concentrations 
of CsA, tacrolimus, and paracetamol increase. However, in the presence of cilastatin, all 
surviving cells keep their capacity to reduce MTT (Fig. 4). Cilastatin is able to counteract 
both the structural and functional damage induced by toxins. 
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Fig. 4. Effect of cilastatin on toxin-induced loss of cell viability determined by the ability to 
reduce MTT (see Methods). Renal proximal tubular epithelial cells were exposed to toxins 
and toxins + cilastatin (200 µg/ml) for 24 hours. Results are expressed as the percentage of 
the value obtained relative to control (without toxins and cilastatin) of at least 3 separate 
experiments. ANOVA: for CsA, *dose effect, p≤0.05; cilastatin effect, p<0.05; for 
tacrolimus, *dose effect, p<0.05; cilastatin effect, p≤0.04; for paracetamol, *dose effect, 
p≤0.05; cilastatin effect, p≤0.05. 
3.2 Cilastatin prevents toxin-induced mitochondrial damage 
The effect of cilastatin on mitochondria may be observed very early after CsA, tacrolimus, or 
paracetamol is added to cell culture plates. In Fig. 5, an inverted IX-80 microscope was fitted 
with a black chamber, a photomultiplier, and a spectrofluorimeter (SML Aminco) to obtain 
absorbance readings at specific wavelengths on single (or small groups of) cells in culture. 
This set-up allows real time follow-up of colorimetric in vivo reactions. 
Recording the first seconds after MTT addition shows the initial kinetics of MTT reduction 
and formazan precipitation, thus offering a first approach to the activity of the 
mitochondrial chain in intact cells. Although not suitable for detailed kinetic studies, this 
method allows a quick check of mitochondrial oxidative activity. 
RPTECs exposed to toxins showed a quick and deep depression in the reduction of MTT 
activity compared with controls (Fig. 5). Coincubation with cilastatin partially recovers this 
effect, although the effect was less visible for paracetamol. Differences are observed even 
during the first 5 minutes of drug additions. 
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Fig. 5. Effect of cilastatin on toxin-induced mitochondrial damage. Changes in the 
mitochondrial oxidative capacity of RPTECs were assessed by MTT reduction at 570 nm. 
The graphs show formation of formazan as detected in isolated cells in real time with no 
treatment (control) and CsA (cyclosporin, 1000 ng/ml), tacro (tacrolimus, 500 ng/ml) and 
para (paracetamol, 600 µg/ml) with or without 200 µg/ml cilastatin, after the incubation 
times on the X-axis. 
3.3 Cilastatin improves long-term recovery and viability of RPTECs after exposure to 
CsA, tacrolimus, and paracetamol 
To know the long-term viability of surviving RPTECs after 24 hours of exposure to CsA, 
tacrolimus, or paracetamol, we tested the ability of those cells to proliferate into new cell 
colonies. Colony-forming units (CFUs) were quantified as specified in Methods. The CFUs 
count decreased after 24 hours of treatment with CsA, tacrolimus, and paracetamol, and this 
decrease was clearly dose-dependent (Fig. 6). If the cells were exposed to toxins in the 
presence of cilastatin, the number of CFUs was significantly greater after 7 days of recovery 
for every CsA, tacrolimus, and paracetamol concentration studied. The intracellular dye was 
extracted, and absorbance was quantified al 595 nm (Fig. 6B, C and D). 
3.4 Cilastatin reduces intracellular accumulation of CsA, tacrolimus, and paracetamol 
In many cases, nephrotoxicity is largely dependent on the intracellular concentration of 
drug reached. As cilastatin is a ligand of the brush border membrane, we investigated 
whether it affected toxin uptake by RPTECs. To test this hypothesis, we measured the 
intracellular content of CsA, tacrolimus, and paracetamol by TDX analysis, as described in 
Methods. Cellular CsA, tacrolimus and paracetamol content increased progressively in a 
dose-dependent manner when RPTECs were incubated for 24 hours in the presence of 
different concentrations of toxins (Fig. 7). Coincubation with cilastatin consistently reduced 
accumulation of CsA, tacrolimus and paracetamol in the cells for every concentration 
studied (Fig. 7). These results confirm that adding cilastatin to primary cultures of proximal 
cells decreases cellular toxin accumulation. This effect may be involved in the reduced 
impact of CsA, tacrolimus, and paracetamol on damage to and survival and death of 
RPTECs. 
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Fig. 6. Cilastatin preserves long-term recovery of toxin-treated RPTECs. A, RPTECs were 
incubated with paracetamol, CsA (cyclosporin), or tacrolimus in the presence or absence of 
200 µg/ml cilastatin for 24 hours. The number of colony-forming units was determined by 
staining with crystal violet after 7 days (the figure shows the experiment with paracetamol). 
B, C, and D, Quantification of crystal violet staining for paracetamol, CsA and tacrolimus, 
respectively. Data are expressed as mean ± SEM; of 3 separate experiments. ANOVA model, 
p<0.0001. p<0.05 vs. control;  *p≤0.05 vs. same data with cilastatin. 
 
 
Fig. 7. Effects of cilastatin on accumulation of toxins by RPTECs. Intracellular accumulation 
was measured in the lysates of RPTECs treated with nephrotoxins for 24 hours, in the 
presence or absence of cilastatin (200 µg/ml), using a specific fluorescence polarization 
immunoassay (TDX). Cilastatin was shown to prevent entry of all nephrotoxins into 
RPTECs. Values were expressed as means ± SEM of drug concentrations (n=4 different 
experiments). ANOVA model, p<0.0001; *, cilastatin effect p<0.05; , dose effect p<0.05. 
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3.5 Effect of cilastatin on lipid rafts distribution 
According to these results, which suggest that cilastatin interferes with intracellular 
administration of the nephrotoxins tested, cilastatin appears to be able to inhibit an 
intracellular nephrotoxin accumulation pathway as a result of its binding to renal DHP-I. 
We explored the possibility that cilastatin, through its interaction with DHP-I and when 
anchored to cholesterol lipid rafts by a glycosyl-phosphate-inositol (GPI) group (Adachi et 
al., 1990; Parkin et al., 2001), could block transport through lipid rafts or interfere with the 
cholesterol lipid raft–dependent endocytic pathway. The expression and cell membrane 
localization of cholera toxin, which specifically binds to its ganglioside GM1 receptor 
present in cholesterol lipid rafts, were assessed using confocal microscopy in RPTECs 
treated for very short periods. In Fig. 8, cholera toxin is identified on the cell surface after 15 
minutes incubation, but it disappeared from the membrane after 1 hour (top) and 
accumulated in a perinuclear position. In the presence of 200 µg/ml cilastatin and after 1 
hour of treatment, cholera toxin was still attached to the membrane, suggesting interference 
with the cholera toxin internalization site. No significant changes in FITC-cholera toxin 
staining patterns were observed at 2.5 hours in the presence of cilastatin. 
 
Fig. 8. Blockade of circulation of cholesterol rafts by cilastatin. This picture shows the change 
in cholera toxin fluorescence internalization over time in control cells and cells incubated in 
the presence of cilastatin (200 µg/ml). Bar, 20 µm.  
4. Conclusion 
We report that cilastatin, a powerful and specific inhibitor of DPH-I, is able to reduce both 
intracellular accumulation and induction of apoptosis by antibiotic, cytotoxic, 
anti-inflammatory, antiretroviral, anesthetic, and immunosuppressive drugs. These findings 
expand our previous results with cisplatin (Camano et al., 2010) and CsA (Perez et al., 2004; 
Tejedor et al., 2007). 
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Cilastatin inhibits the activity of DPH-I, but not of DPH-4, in the brush border of renal 
RPTECs (Fig. 9).  
 
Fig. 9. Effect of cilastatin on the activity of dehydropeptidase I and IV. Activities were 
determined by the hydrolysis of specific substrates. Results are expressed as a percentage of 
enzyme activity compared to untreated controls (100% activity) and as the mean ± SEM of 3 
experiments. ANOVA model, p<0.0001. * p<0.01 vs. the same data without cilastatin. 
Although this inhibition is probably irrelevant in the degree of nephroprotection observed—
none of the nephrotoxins studied have a chemical structure that could potentially be 
affected by dipeptidase activity—binding to DPH-I may partially explain this protection. 
DPH-I is anchored to brush border lipid rafts (Pang et al., 2004; Parkin et al., 2001). Binding 
of FITC-labelled B-cholera toxin to lipid rafts leads to their rapid internalization. However, 
internalization does not occur in the presence of cilastatin.  
This mechanism is probably behind the reduction observed in the intracellular concentration 
of the different drugs analyzed. 
We previously showed that cilastatin modifies brush border membrane fluidity by 
interfering with membrane-bound cholesterol (Perez et al., 2004). 
The drugs tested in Fig. 1 have many different chemical structures, and their mechanisms of 
cell permeation are not well established in some cases. However, for all those drugs, 
intracellular concentrations were measured and cilastatin always reduced intracellular 
accumulation. By inhibiting lipid raft–dependent vesicle circulation, cilastatin seems able to 
reduce luminal entry of drugs, even if they are not substrates for DPH-I activity. 
This interference with drug entry may explain the almost instantaneous protection observed 
in the real-time experiments of MTT reduction. MTT reduction relies on mitochondrial 
oxidative chain integrity. When single cell oxidative capacity is recorded in real time, 
addition of the toxin inhibits MTT reduction activity relative to the single control cell, and 
this is evident from the first seconds. Cilastatin partially protects against this effect. The 
quick time course of the effect strongly suggests that a mechanism of cilastatin inhibits drug 
intake by the cell. 
However, other mechanisms may be implicated in the broad renal protection observed. We 
recently published that, when exposed to toxic concentrations of cisplatin, RPTECs increase 
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expression of Fas and Fas L. Fas targets brush border lipid rafts (Dimanche-Boitrel et al., 
2005), binds its ligand, and triggers the extrinsic pathway of apoptosis. Internalization of 
Fas/Fas L seems a necessary step (Camano et al., 2010). 
Cilastatin reduced cisplatin-induced cell apoptosis but not cell necrosis (Camano et al., 
2010). When the extrinsic apoptosis pathway was checked, the initial step blocked by 
cilastatin was Fas L/Fas internalization (Camano et al., 2010). 
Cilastatin reduces apoptosis (nuclear damage, nucleosome formation, MTT reduction 
capacity) and ameliorates surviving cell recovery. Both reductions in drug intake by 
proximal cells and blockade of lipid raft internalization are probably involved in these 
protective actions (Fig. 10). 
 
 
Fig. 10. Diagram of the possible protective mechanism of cilastatin. Cilastatin is a 
dehydropeptidase-I inhibitor used in human clinical practice combined with imipenem. 
Dehydropeptidase inhibition affects the structure of lipid rafts by preventing hydrolysis of 
the lactam ring and inhibits the absorption of imipenem and other nephrotoxic drugs, thus 
reducing their renal toxicity.  
Protection by cilastatin depends on its interaction with DPH-I, an enzyme that is found 
almost exclusively in proximal tubules. Therefore, cilastatin-induced nephroprotection is 
specific for tissue and cell type, but not for the drug tested. 
More research is necessary to confirm the mechanism of protection, the ability to protect in 
animal models of acute renal failure, and the absence of an effect on the pharmacological 
targets of tested drugs. Nevertheless, cilastatin offers a new protective strategy, as it is a 
tissue-specific designed drug, with unexpected tissue-specific antiapoptotic actions. 
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